Nic Russell's life changed forever in April 2005 when her daughter Kenzie was diagnosed with cancer. Two months later Nic too was diagnosed.
Kenzie died at christmas that year, so this is always a very challenging time for Nic, and she thinks more about the families facing the same trauma at christmas time - and wants to give them the gift of support at this time of year.
The American Society of Clinical Oncology (ASCO) has listed two breakthroughs in breast cancer research among the top 17 cancer advances for 2012.
The results come in the Society’s annual report highlighting major research advances in cancer treatment and care this year.
A lower total dose of radiotherapy, delivered in fewer, larger treatments, is as safe and effective at treating early breast cancer as the international standard dose, according to a major study.
The results of the Cancer Research UK START trial, which involved nearly 4,500 British women, were presented at the recent San Antonio Breast Cancer Symposium.
New Zealand women with triple negative metastatic breast cancer may be eligible to participate in a clinical trial examining the benefits of the drug Tamoxifen to control the growth and spread of cancer cells.
About 15 per cent of all breast cancers are defined as triple negative, which means the cancer is not driven by either of the hormones oestrogen or progesterone, nor by the HER2 protein.
Breast Cancer Network is losing one of their longest standing committee members.
New research results show that women with oestrogen receptor positive breast cancer who take the drug tamoxifen for ten years rather than five, have a reduced risk of breast cancer recurring and better overall survival rates.
The findings of the ATLAS (Adjuvant Tamoxifen – Longer Against Shorter) study were presented this week at the renowned San Antonio Breast Cancer Symposium.
What to do about your job while you have treatment for breast cancer can be a further stress for many women who are faced with a breast cancer diagnosis.
Many women worry about telling their employers about a diagnosis of breast cancer. And the list of concerns can be long:
A clinical trial comparing a shorter course of partial breast irradiation with standard whole breast irradiation has found that those who received the faster partial treatment were more likely to report side effects and poorer cosmetic outcomes.
New Zealand women were involved in the RAPID clinical trial which compared partial breast irradiation given twice daily over five to eight days with whole breast irradiation given daily over three to five weeks.
The quality of a woman’s social networks — the personal relationships that surround an individual — appear to be just as important as the size of her networks in predicting breast cancer survival, scientists report in the current issue of Breast Cancer Research and Treatment.
Breast Cancer Aotearoa Coalition committee member, Julie Graham, attended the recent Breast cancer Network Australia Strength to Strength National Conference.
